Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Lupin Earnings Call: Key Takeaways

Lupin delivered a record-breaking FY26 with 32% revenue growth and 68% EBITDA surge, driven by US generic exclusivity and robust India prescription growth.

Why this was an Alfa AlertEBITDA margin beat: Guided 27-28% for FY26, achieved 29.7% (approx. 6% above guided upper end).
Highlights
Revenue growthFY26 revenue grew 23% YoY; Q4 up 32% YoY.
MarginsFY26 EBITDA margin hit 29.7%; FY27 guided down to ~25%.
Demand visibilityStrong outlook for complex generics and biosimilars in US and Europe.
Management confidenceBalanced and transparent regarding FY27 margin headwinds and competitive pressures.

Growth

FY26 revenue grew 23% YoY; US sales up 40% led by Tolvaptan and Mirabegron; India prescription business grew 14.5%.

Outlook

FY27 guidance: high single-digit revenue growth with ~25% EBITDA margins; 50+ US product launches planned over 3 years.

Risks

EBITDA margins guided lower at 25% for FY27 due to expected generic competition in US key products.

Source

Earnings Call filed with NSE, NSE: LUPIN. Summary written with AI assistance from the document.

Read the document ↗

Lupin Ltd: key numbers

Share price
₹2,092.00
Market cap
₹95,665 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
17.3×Sector 50.4×
Promoter holding
46.85%-0.01% QoQ
FII holding
22.42%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
16:14 IST BSE
Employee Stock Options

Lupin Employee Stock Options

Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.

17:38 IST NSE
Product Launch

Lupin Product Launch

Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.